Oesophageal Cancer Clinical Trial
Official title:
A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer
This is a trial of adoptive T cell therapy using the patient's own T cells, genetically
engineered to target the tumour associated antigen NY-ESO-1 (New York esophageal squamous
cell carcinoma 1). Eligible patients will undergo leukapheresis (a process to remove white
blood cells) to retrieve sufficient T cells which will be gene modified and expanded in the
laboratory. Patients will undergo preconditioning chemotherapy with cyclophosphamide
(60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The NY-ESO-1
gene modified cells will be re-infused on day 0 and the patients will receive up to 14 doses
of intravenous Interleukin2 (100000 U/kg) from day 0 to day 4.
The primary objective of response rate according to Response Evaluation Criteria in Solid
Tumours (RECIST) 1.1 criteria will be assessed by CT scans carried out at week 6, week 12 and
at 12 weekly intervals thereafter.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05685862 -
Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit
|
||
Recruiting |
NCT01795768 -
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
|
Phase 2 | |
Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
Recruiting |
NCT03978377 -
Cardiopulmonary Toxicity of Thoracic Radiotherapy
|
||
Active, not recruiting |
NCT03653052 -
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
|
Phase 2 | |
Recruiting |
NCT05489250 -
The PLATON Network
|
||
Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
Recruiting |
NCT01843829 -
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
|
Phase 2 | |
Completed |
NCT02382237 -
Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition
|
N/A | |
Completed |
NCT01915693 -
ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study
|
Phase 3 | |
Recruiting |
NCT04517448 -
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
|
||
Recruiting |
NCT04232735 -
Evidence Based Information Provision to Improve Decision Making After Oesophagogastric Cancer Diagnosis (SOURCE)
|
N/A | |
Recruiting |
NCT05642819 -
REVOLUTION Surgery (REVOLUTION Surgery)
|
||
Recruiting |
NCT04001478 -
Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
|
||
Recruiting |
NCT02741856 -
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05600608 -
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome
|
N/A | |
Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06046846 -
Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer
|
N/A | |
Recruiting |
NCT05357846 -
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
|
Phase 3 |